Journal article
Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth
Oncotarget, Vol.6(6), pp.4266-4273
02/28/2015
DOI: 10.18632/oncotarget.2887
PMCID: PMC4414188
PMID: 25738355
Abstract
Increased adrenergic signaling facilitates tumor progression, but the underlying mechanisms remain poorly understood. We examined factors responsible for stress-mediated effects on monocyte/macrophage recruitment into the tumor microenvironment, and the resultant effects on tumor growth. In vitro, MCP1 was significantly increased after catecholamine exposure, which was mediated by cAMP and PKA. Tumor samples from mice subjected to daily restraint stress had elevated MCP1 gene and protein levels, increased CD14+ cells, and increased infiltration of CD68+ cells. hMCP1 siRNA-DOPC nanoparticles significantly abrogated daily restraint stress-induced tumor growth and inhibited infiltration of CD68+ and F4/80+ cells. In ovarian cancer patients, elevated peripheral blood monocytes and tumoral macrophages were associated with worse overall survival. Collectively, we demonstrate that increased adrenergic signaling is associated with macrophage infiltration and mediated by tumor cell-derived MCP1 production.
Details
- Title: Subtitle
- Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth
- Creators
- Guillermo N Armaiz-Pena - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAVianey Gonzalez-Villasana - Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAArchana S Nagaraja - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USACristian Rodriguez-Aguayo - Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USANouara C Sadaoui - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USARebecca L Stone - Department of Obstetrics and Gynecology, The John Hopkins University, Baltimore, MD 21287, USAKoji Matsuo - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA 90089, USAHeather J Dalton - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USARebecca A Previs - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USANicholas B Jennings - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAPiotr Dorniak - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAJean M Hansen - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAJesusa M G Arevalo - Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USASteve W Cole - Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USASusan K Lutgendorf - Department of Psychology, Obstetrics and Urology, and Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa 52242, USAAnil K Sood - Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USAGabriel Lopez-Berestein - Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
- Resource Type
- Journal article
- Publication Details
- Oncotarget, Vol.6(6), pp.4266-4273
- DOI
- 10.18632/oncotarget.2887
- PMID
- 25738355
- PMCID
- PMC4414188
- NLM abbreviation
- Oncotarget
- ISSN
- 1949-2553
- eISSN
- 1949-2553
- Publisher
- United States
- Grant note
- T32 CA101642 / NCI NIH HHS CA104825 / NCI NIH HHS R01 CA104825 / NCI NIH HHS P50CA083639 / NCI NIH HHS CA016672 / NCI NIH HHS P50 CA098258 / NCI NIH HHS 5U54CA151668 / NCI NIH HHS R01 CA109298 / NCI NIH HHS U54 CA096300 / NCI NIH HHS CA109298 / NCI NIH HHS U54 CA 096300-08 / NCI NIH HHS 5RC2GM09259 / NIGMS NIH HHS R01 CA140933 / NCI NIH HHS CA140933 / NCI NIH HHS P30 CA016672 / NCI NIH HHS U54CA151668 / NCI NIH HHS P50 CA093459 / NCI NIH HHS U54 CA151668 / NCI NIH HHS P50 CA083639 / NCI NIH HHS P50CA098258 / NCI NIH HHS U54 CA096297 / NCI NIH HHS U54CA96297 / NCI NIH HHS U54CA96300 / NCI NIH HHS CA101642 / NCI NIH HHS
- Language
- English
- Date published
- 02/28/2015
- Academic Unit
- Psychological and Brain Sciences; Iowa Neuroscience Institute; Obstetrics and Gynecology; Urology
- Record Identifier
- 9984065769102771
Metrics
22 Record Views